Completed studies
- Phase I formulation finding inhalation dose study for pk in healthy subjects that were smokers
- Phase I pilot formulation study for pk, safety and tolerability in 18 healthy subjects
- Phase I parallel group study for pk, safety and tolerability in 39 healthy subjects
- Phase I parallel group study for pk in healthy subjects and patient subjects with varying degrees of renal impairment
- Phase I 5 way crossover study for pk, safety, tolerability, bioavailability and food effect in 24 healthy subjects
- Phase I first in man SAD parallel group study for pk, safety, tolerability and food effect in 68 healthy subjects
- Phase I 2 part dose finding study for safety and tolerability in 35 healthy and CA patient subjects
- Phase I pilot study in patient subjects with Chronic Hepatitis C
- Phase I parallel group study in patient subjects with varying degrees of renal impairment
- Phase I first in man SAD study for pk, pd, safety and tolerability in 56 healthy subjects
- Phase I first in man MAD study for pk, pd, safety and tolerability in subjects with allergic rhinitis
- Phase I multi formulation, 4 period, 4 sequence crossover study for pk and pd in 32 healthy subjects
- Phase I 2 period crossover study for pk and pd in CA patient subjects
- Phase I parallel group study for pk pd, safety and tolerability in 35 healthy and renaly impaired subjects
- Phase I/IIa SC dose study for pk, pd, safety and tolerability in RA patient subjects
- Phase I SAD pk study in patient subjects with varying degrees of renal impairment
- Phase I SAD study for pk, pd, safety and tolerability in 21 healthy subjects
- Phase I/IIa dose finding study for pk, pd, safety and toloerability of single and repeat IV doses in RA patient subjects
- Phase I multi-period crossover study for food effect, pk, safety and tolerability in 24 healthy subjects
- Phase I MAD study for pk, pd, safety and tolerability in 30 healthy subjects
- Phase I bioavailability study for pk, pd, safety and tolerability in 28 healthy subjects
- Phase I study for pk, pd, safety and tolerability in patient subjects with Type 2 Diabetes
- Phase I two-way crossover study for pk and bioavailability in 24 healthy subjects
- Phase I SAD multi-period study for pk, pd, safety and tolerability and food effect in 36 healthy subjects
- Phase I MAD study for pk, pd, safety, and tolerability in 24 healthy subjects
- Phase I study for pk, pd, safety and toloerability in 32 healthy and renaly impaired subjects
- Phase II study for safety, tolerability and efficacy in 5 patient subjects with breast cancer and bone metastases
- Phase I multi sequence, 3 period crossover study for pk, pd, safety, tolerability and bioavailability of multiple formulations in 36 healthy subjects
- Phase I/IIa SAD and MAD study for pk, pd, safety and tolerability in 53 healthy and HCV patient subjects
- Phase I multi sequence, multi period and multi treatment bioavailability, pk and safety study in 30 healthy subjects
- Phase I 6 period, 6 treatment and 6 sequence crossover study for safety and palatability in 12 healthy subjects
- Phase I SAD parallel group study for pk, pd, safety and tolerability in 100 healthy subjects
- Phase I multi dose, multi period crossover study for safety, pk and tolerability in 16 healthy subjects
- Phase I safety, tolerability and pk study in 9 patient subjects with Hormone Refractory Prostate Cancer and Metastatic Bone Disease
- Phase I sequential, single IV and subcutaneous dose study for safety, tolerability and pk in 84 healthy subjects
- Phase I single dose pk and safety study in 32 renally impaired patients and healthy subjects
- Phase I 3 way crossover study to investigate bioavailability in 15 healthy subjects
- Phase I single dose study for safety and pk in 18 patient subjects with varying degrees of renal impairment
- Phase I study of pk, safety and tolerability in 10 patient subjects with severe renal impairment
- Phase II multiple dose study for safety, tolerability and efficacy in patient subjects with Type II Diabetes
- Phase I multiple IV and oral dose study of the tolerability, safety and pk in 32 subjects with varying degress of renal impairment
- Phase I pk and pd study in 12 healthy subjects
- Phase I bioavailability, multi-formulation, multi-dose study in 68 healthy subjects
- Phase I multiple oral dose study of the safety, tolerability, pk and pd effect in 48 healthy subjects
- Phase I single dose pk study in 30 subjects with varying degrees of renal impairment
- Phase I drug - drug interaction study on pk in 18 healthy subjects
- Phase I SAD (radio labelled) study of excretion balance and pk in 8 healthy subjects
- Phase I SAD study assessing safety, tolerability and pk in 46 healthy subjects
- Phase I SAD study for safety, tolerability and pk in 24 healthy subjects
- Phase I SAD study for safety, tolerability, pk and pd in 72 healthy subjects
- Phase I ECG study on QT evaluation in 74 healthy subjects
- Phase I bioequivalence study of multiple formulations in 4 kidney transplant recipient subjects
- Phase I safety and pk study in 8 Hepatitis C patient subjects
- Phase I SAD and MAD study for safety, tolerability and activity, food effect and pk of multiple formulations in 103 healthy subjects
- Phase I Bioavailability and food effect study, 5 way cross over in 24 healthy volunteers
- Phase I pk SAD (4 dose levels) and MAD (4 dose levels) study in 64 healthy volunteers
- Phase I MAD pk/pd study, 4 dose levels in 48 healthy volunteers
- Phase II Multiple inhaled dose, 4 period crossover study, responsiveness to drug measured by AMP challenge in 9 mild asthmatic patients
- Phase I Multiple dose DDI study in 12 rheumatoid arthritis patients
- Phase I DDI in 12 healthy male volunteers
- Phase I Bioavailability study, 4 cohorts of 20 healthy volunteers
- Phase I bioavailability, food effect study in 15 healthy volunteers
- 5 way crossover pd/pk study in 15 subjects, mild to moderate asthmatics
- Phase I pd/pk study in 24 predialysis patients
- Phase I pk study in Hepatitis C patients with normal and impaired renal function
- Phase II/III drug interaction study in rheumatoid arthritis patients
- Phase I pk study in 18 healthy volunteers
- Phase I MAD study in patients with Type 2 diabetes mellitus
- Phase I 2 period, food effect study in 12 healthy elderly
- Phase I pk study in 30 volunteers with varying degrees of renal failure
- Phase I bioequivalence study in 28 healthy males
- Assessment of efficacy of implanted device for monitoring of glucose levels in Type 1 diabetes patients
- Phase I 8 period SAD study, 2 period food effect crossover in 76 patients
- Phase I biovailability study in 18 healthy volunteers
- Phase III safety and efficacy study in 6 multiple sclerosis patients
- Phase I 5 period crossover study in mild to moderate asthmatics
- Phase III in 20 postmenopausal osteoporotic women
- Phase I SAD study, 5 dose levels in 40 healthy volunteers
- Phase I 5 period, food effect study in 16 healthy volunteers
